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Introduction:
What is the topic?
Malignant 
Hyperthermia 


































• He	was	discharged	on	Day		7postinjury.	Patient	was	neurologically	intact	and		scheduled	to	follow	up	for	his	orthopedic	injuries(Luckey-Smith & High, 2018)
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Pathophysiological Processes 
Normal 
Physiology 
• In	a	normal	muscle	contraction,	an		action	potential	causes	membrane	depolarization	which	releases	calcium		from	the	sarcoplasmic	reticulum	(SR).	
• The	calcium	moves	into	the	sarcoplasm	via	the	ryanodine	receptors.	The	receptor	is	a	voltage-gated	ion	channels.	
• The	calcium	interacts	with	the	troponin-tropomyosin	complex.	It	creates	the	cross-bridge	between	actin	and	myosin	and	a	muscle	contraction	occurs.
• At	the	end	of	a	muscle	contraction,	calcium	migrates	back	into	the	sarcoplasmic	reticulum	,	and	another	stimulus	is	needed	to	release	calcium		for	a	muscle	contraction	(	Schneiderbanger	et	al.,	2014).	
Underlying  
Pathophysiology 
• MH		is	a	rare	yet	life	threatening	autosomal	dominant	disorder	(affected	individual	has	one	copy	of	a	mutant	gene	and	one	normal	gene	on	a	pair	of autosomal	chromosomes)	(Nagelhout	&	Elishia,	2018,	p.	773).	
• MH	occurs	because	of	a	a	mutation	on	the	ryanodine	receptor,	which	is	the	major	calcium	release	channel	of	the	sarcoplasm	reticulum	(Nagelhout	&	Elishia,	2018,	p.	774).	
• The	anesthetic	agents	trigger	these	mutations,	and	in	turn,	cause	an	atypical	increase	in	release	of	calcium	from	the	sarcoplasmic	reticulum	of	skeletal	muscle	cells	(Mullins,	2018)
• This	results	in	sustained	muscle	contraction	and	abnormal	muscle	metabolism.		
• The	response	leads	to		hypermetabolic	activity	of		increased	oxygen	consumption,	carbon	dioxide	production,	heat	production,	and	lactic	acidic	build	up.	Results	can	then	lead	to	systemic	acidosis,	hyperkalemia,	and	hyperthermia	(Smith	et.	al,	2018).
Signs and Symptoms
• MH	may	present		anytime		during		general	anesthesia	and	the	early	postoperative	phase						(	Mullins,	2018)
• Early	and	specific	sign	of	MH	is		an		unexplained	rise	in	end-tidal	CO2	levels	with	increased	ventilation.	If	succinylcholine	is	used	,the		rise	in	CO2	may	be	more	rapid	(Smith,	et	al,	2018)
• Other	symptoms	include,	tachycardia	and	dysrhythmia,	abrupt	rise	in	core	body	temperature,	generalized		skeletal	muscle	rigidity	and	rhabdomyolysis	(	Smith	et.	al,	2018)
• Progression	of		the	crisis	leads	to	respiratory	and	metabolic	acidosis,	increased	serum	potassium,	elevated	creatine	kinase		levels,	and	myoglobinuria	may		occur.	The		patient	may	also	suffer	from	acute	renal		failure	and/or	disseminated	intravascular	coagulation	(	Smith	et.	al,	2018)	
• The	severity	of	a	MH	crisis	depends	on	how	quickly	the	disease	process	is	suspected	and	how	rapidly	an	appropriate	treatment	is	initiated	(	Schneiderbanger	et	al.,	2014).
• Nurses	should	coordinate	staff	efforts	toward	three	priorities:	dantrolene	preparation,	cooling	the	patient,	and	preparing	for	transport.
• Priority	of	treatment	begins		by	hyperventilating	the	patient	with	100%	oxygen	and	administering	a	dose	of	dantrolene	sodium.
• Dantrolene	is	a	skeletal	muscle	relaxant	that	depresses	muscle	contraction	by	decreasing	intracellular	calcium	concentration	(National	Institute	s	of	Health,	2018).	
Implications for 
nursing care
• The	prevalence	of	MH	is	estimated	at	1:100,000	administered	anesthetics,	but	this	is	likely	underreported.	(	Borth,	2019)
• Half	of	the	patients	diagnosed	with	MH	have	received	a	prior	anesthetic	without	manifesting	MH.	(	Borth,	2019)
• Without	treatment,	the	mortality	rate	for	an	acute	MH	episode	is	as	high	as	80% (	Borth,	2019)
• Complications	increase	3X	per	every	2°C	increase	in	temperature	and	1.6	X	per	30-minute	delay	in	dantrolene	administration	(	Borth,	2019)
• All	staff	members	involved	in	the	care	of	patients	receiving	MH-triggering	agents	should	receive	annual	education	on	MH	treatment	(	Borth,	2019)
• Although	MH	is	a	rare	medical	emergency,	it	is	vital	that	clinicians	and	patients	are	prepared	and	educated	for	the	surgical	procedure	and	the	risk	for	complications	with	a	detailed	plan	in	place	
Conclusion
Implications
for nursing 
care cont.
• Once		stabilized,	patient	should	be	prepared	to	go	to	the	ICU	(	Borth,	2019)	à
§ decreased	heart	rate
§ decreased	end-tidal	carbon	dioxide	(EtCO2)
§ resolution	of	hyperkalemia
• Regular	MH	drills	should	be	performed	to	demonstrate	that	staff	can	mobilize	MH	supplies	(Borth,	2019)
• It	is	required	that		anesthesia	staff	along	with	the	registered	nurses	working	in	the	PACU	must	know	the	response	plan	for	an	MH	event	(Borth,	2019)
•
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